Waheed Asghar

Waheed Asghar is a DMPK Metabolism Scientist at FMC Corporation since April 2021, specializing in human risk assessment and PBPK modeling, with extensive experience in providing drug disposition data, conducting PK and metabolism studies, and guiding chemical modifications for improved ADME properties. Previous roles include DMPK Research Scientist at QPS Holdings, LLC, where responsibilities encompassed ADME and clinical studies, and PK-PD Scientist at Osteometabolix Pharmaceuticals, focusing on bone-targeting biologics. Waheed also served as a Research Fellow at the University of Alberta, investigating bone-targeting nanoparticles and cancer biomarkers. An academic background includes a Ph.D. in Pharmaceutical Sciences from the University of Alberta and experience as a lecturer and graduate research assistant, where Waheed managed laboratory protocols and mentored students.